Loading…
← CockpitCompetitor Analysis › 600161.SS Beijing Tiantan Biological Products Corporation Limited Class AOpen in the cockpit ↗

Beijing Tiantan Biological Products Corporation Limited Class A600161.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

State-owned Chinese plasma-products maker under China National Biotec Group, producing albumin, immunoglobulin and vaccines.

≈ A state-owned Chinese CSL BehringMomentum strong 78
Mkt cap
$3.47B
US dollars, full cap
Free float
44%
of shares outstanding
$/day
$23.9M
20-day average traded
Fwd P/E
33.1×
forward earnings
ROIC−WACC
+2.4 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥11.94
1D-0.7%
1W-3.2%
1M-3.9%
3M-6.5%
6M-13.3%
YTD-26.9%
1Y-35.5%
ATR %2.1%
52w lowhigh36.1% off high

What Beijing Tiantan Biological Products does

State-owned Chinese plasma-products maker under China National Biotec Group, producing albumin, immunoglobulin and vaccines.

Plasma products carry the company: albumin and immunoglobulin are extracted from collected blood plasma, so sales depend on how much its licensed collection stations can gather. Hospitals and distributors buy them, with vaccines a smaller line. It sits inside the state-owned Sinopharm group through China National Biotec.

In one line: A state-owned Chinese CSL Behring.

Products and services

  • Human albumin
  • Immunoglobulin
  • Vaccines

Customers

  • Hospitals
  • CDC/distributors

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Plasma products & vaccines

What could go right

  • Plasma collection scale-up

What could go wrong

  • State-enterprise capital-allocation drag
  • Procurement price pressure

Moat: narrow (regulatory licence, scale). State-backed plasma-collection network under Sinopharm/CNBG with licensed collection stations nationwide.

Headquarters: Beijing, China · Employees: 5,205

Named competitors

Beijing Tiantan Biological Products at a glance

Size Beijing Tiantan Biological Products (600161.SS) is a China Health Care company (Biotechnology) with a market value of $3.47B, the 703rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.94 on 18 Nov 2026.

Performance Over six months the shares fell 13.3%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 12.8% over the last twelve months (peer median +8.3%); the operating margin is 21.4% (peer median -35.0%).

Valuation It trades at 33.1× forward earnings against a peer median of 29.4× (4th most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 101600161.SS 88
Six months, rebased to 100: Beijing Tiantan Biological Products against the median of its 20 peers (local-currency closes).

Beijing Tiantan Biological Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.56BCN¥6.14BCN¥6.01BCN¥5.13BCN¥4.22B
Revenue growth—+2%+17%+22%—
Gross profitCN¥2.39BCN¥2.58BCN¥3.19BCN¥2.52BCN¥2.00B
EBITDAn/aCN¥2.22BCN¥2.83BCN¥1.98BCN¥1.49B
Net incomeCN¥700MCN¥1.09BCN¥1.55BCN¥1.11BCN¥881M
Free cash flowCN¥41.3M-CN¥230M-CN¥226MCN¥1.35B-CN¥206M
Capital expenditureCN¥619MCN¥606MCN¥1.07BCN¥1.08BCN¥1.35B
Total debtCN¥79.2MCN¥187MCN¥59.4MCN¥147MCN¥409M

Quarterly statements and history in the cockpit →

Beijing Tiantan Biological Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%IOVAIRONABCL6919RLAYELVN603127TNGX002007VIRPXERSCRSP6696ADMATLXDYNDNLIRUBICON6033922228600161.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Tiantan Biological Products is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×603127002007VIRPXERSADMATLXRUBICON600161.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Tiantan Biological Products is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%002007VIRPXERSADMA600161.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Tiantan Biological Products is the large dot.

Beijing Tiantan Biological Products competitors and peer comparison

Head to head with its named competitors (600161.SS vs 002007.SZ vs 002252.SZ vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Beijing Tiantan Biological Products 600161.SS$3.47B-13%-13%21%33.1×2.2%
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%26.7×15.8%
Shanghai RAAS Blood Products 002252.SZ$4.57B-15%-22%17%12.8×n/a
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%

How Beijing Tiantan Biological Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Tiantan Biological Products against its 20 peers (data as of 18 Nov 2026)
Measure600161.SSPeer medianRank in peer set
1-month return-3.9%-6.1%10th highest of 21
6-month return-13.3%+1.1%6th lowest of 21
Distance from 52-week high-36.1%-31.6%8th lowest of 21
Revenue growth (TTM)-12.8%+8.3%4th lowest of 16
Operating margin21.4%-35.0%2nd highest of 16
Forward P/E33.1×29.4×4th most expensive of 8
Growth the price implies (Req g, 7 yrs)2.2%10.8%2nd least demanding of 5
Growth delivered (Del g)+12.5%+37.0%3rd highest of 5
Hurdle (Req g minus delivered)-10.3 pp-22.2 pp3rd least demanding of 5
ROIC minus cost of capital+2.4 pp-10.9 pp4th highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%29.4×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%n/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a

Questions

Who are Beijing Tiantan Biological Products's main competitors?
Named competitors: Hualan Biological Engineering (002007.SZ), Shanghai RAAS Blood Products (002252.SZ), CSL Behring (CSL.AX). The cockpit's measured peer set (industry) also includes Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), AbCellera Biologics (ABCL), Caliway Biopharmaceuticals (6919.TW), Relay Therapeutics (RLAY), Enliven Therapeutics (ELVN).
Is Beijing Tiantan Biological Products expensive compared with its peers?
On forward p/e it trades at 33.1× against a peer median of 29.4×, 4th most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Beijing Tiantan Biological Products stock performed?
Over six months to 18 Nov 2026 the shares returned -13.3% against +1.1% for the median peer; over one year -35.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.